Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated
